IP Library Granted Patent US 9,139,618
Granted Patent B2
US 9,139,618 · App. 13/976,265 · Granted Sep 22, 2015

Salmonid alphavirus protein E2

Inventor: Stephane Villoing (Ulset, NO)
Assignee: Intervet Inc.
C07K14/005A61K39/12A61K39/295C12N7/00A61K2039/552A61K2039/55566C12N2770/36122C12N2770/36134C12N2770/36151
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,139,618
App. No.
13/976,265
Granted
Sep 22, 2015
Kind
B2
Abstract

The present invention relates to Salmonid alphavirus E2-protein expressed in a bacterial expression system, its use in medicine, vaccines comprising such protein, methods for the preparation of such proteins and methods for the preparation of vaccines comprising such proteins.

Claims (26)

1. A Salmonid Alphavirus (SAV) E2-protein obtained by a process comprising the steps of:

1) expressing a DNA molecule comprising a gene encoding the Salmonid Alphavirus E2-protein in a bacterial expression system,

2) denaturing said protein and

3) refolding said protein in the presence of L-arginine;

wherein said SAV E2-protein is capable of inducing protection in fish against infection with Salmonid Alphavirus.

2. The Salmonid Alphavirus E2-protein of claim 1 , wherein the bacterium used in the bacterial expression system is E. coli.

3. The Salmonid Alphavirus E2-protein of claim 2 , wherein at least part of a SAV E3-protein is still attached to the E2-protein.

4. A method of protecting a fish against Salmonid Alphavirus virus (SAV) infection comprising administering said Salmonid Alphavirus E2-protein of claim 2 to the fish.

5. A vaccine for the protection of salmonid fish against Salmonid Alphavirus infection, wherein said vaccine comprises an immunogenic amount of Salmonid Alphavirus E2-protein of claim 2 and a pharmaceutically acceptable carrier.

6. The Salmonid Alphavirus E2-protein of claim 1 , wherein at least part of a SAV E3-protein is still attached to the E2-protein.

7. A method of protecting a fish against Salmonid Alphavirus virus (SAV) infection comprising administering said Salmonid Alphavirus E2-protein of claim 6 to the fish.

8. A vaccine for the protection of salmonid fish against Salmonid Alphavirus infection, wherein said vaccine comprises an immunogenic amount of Salmonid Alphavirus E2-protein of claim 3 and a pharmaceutically acceptable carrier.

9. A method of protecting a fish against Salmonid Alphavirus virus (SAV) infection comprising administering said Salmonid Alphavirus E2-protein of claim 1 to the fish.

10. A vaccine for the protection of salmonid fish against Salmonid Alphavirus infection, wherein said vaccine comprises an immunogenic amount of Salmonid Alphavirus E2-protein of claim 1 and a pharmaceutically acceptable carrier.

11. The vaccine of claim 10 , wherein said vaccine comprises an adjuvant.

12. The vaccine of claim 11 , wherein said vaccine additionally comprises an immunogenic amount of at least one other antigenic component or genetic information encoding such an antigenic component.

13. The vaccine of claim 12 , wherein said other antigenic component or genetic information encoding such an antigenic component is selected from the group consisting of infectious pancreatic necrosis virus (IPNV), striped jack nervous necrosis virus (SJNNV), infectious haematopoietic necrosis virus (IHNV), viral haemorrhagic septicaemia virus (VHSV), Pancreas Disease virus (SPDV), infectious salmon anaemia virus (ISAV), Flexibacter columnaris, Edwardsialla ictaluri, E. tarda, Yersinia ruckeri, Pasteurella piscicida, Vibrio anguillarum, Aeromonas salmonicida and Renibacterium salmoninarum.

14. A method for preparing a vaccine comprising the Salmonid Alphavirus E2-protein of claim 11 , comprising mixing said Salmonid Alphavirus E2-protein with a pharmaceutically acceptable carrier.

15. The vaccine of claim 10 , wherein said vaccine additionally comprises an immunogenic amount of at least one other antigenic component or genetic information encoding such an antigenic component.

16. The vaccine of claim 15 , wherein said other antigenic component or genetic information encoding such an antigenic component is selected from the group of infectious pancreatic necrosis virus (IPNV), striped jack nervous necrosis virus (SJNNV), infectious haematopoietic necrosis virus (IHNV), viral haemorrhagic septicaemia virus (VHSV), Pancreas Disease virus (SPDV), infectious salmon anaemia virus (ISAV), Flexibacter columnaris, Edwardsialla ictaluri, E. tarda, Yersinia ruckeri, Pasteurella piscicida, Vibrio anguillarum, Aeromonas salmonicida and Renibacterium salmoninarum.

17. A method for preparing a vaccine comprising the Salmonid Alphavirus E2-protein of claim 15 , comprising mixing said Salmonid Alphavirus E2-protein with a pharmaceutically acceptable carrier.

18. A method for preparing a vaccine comprising the Salmonid Alphavirus E2-protein of claim 10 , comprising mixing said Salmonid Alphavirus E2-protein with a pharmaceutically acceptable carrier.

19. A method for the preparation of a Salmonid Alphavirus E2-protein of claim 1 , wherein said method comprises the steps of:

1) expressing a DNA comprising a gene encoding a Salmonid Alphavirus E2-protein in a bacterial expression system,

2) denaturing said protein and

3) refolding said protein in the presence of L-arginine.

Assignments (3)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2014
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 031957/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2014
From: VILLOING, STEPHANE
To: INTERVET INTERNATIONAL B.V.
Reel/Frame 031951/0636 →
Priority Claims (1)
EP 10197232 · Dec 29, 2010 · regional
Continuity (2)
Provisional Application 61430299 · Jan 6, 2011
Related Publication 20130337007A1 · Dec 19, 2013